My Companies
Notification
Account
Log Out
Login
Biocon commercially launched Yesafili™, its interchangeable biosimilar aflibercept 2 mg, in the U.S. on August 3, 2026, targeting the ~$5.9 bn Eylea® market. Context: fulfills the anticipated biosimilar launch catalyst.
Biocon Launches Yesafili Aflibercept Biosimilar in United States
Mylan Sells Entire 5.64% Biocon Stake In Open Market Deal